De Novo Pharmaceuticals Overview

  • Founded
  • 1999
  • Status
  • Out of Business
  • Employees
  • 11
  • Latest Deal Type
  • Out of Business

De Novo Pharmaceuticals General Information


Provider of a drug discovery platform designed to provide computerized drug design systems. The company's drug discovery platform focuses on small molecule therapeutics and a suite of software tools for the analysis of structural information on a protein target, providing drug developers a greater scope to optimize molecules.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Compass House, Vision Park
  • Histon
  • Cambridge CB4 9ZR
  • England, United Kingdom
+44 01223 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

De Novo Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Aug-2015 000.00 Completed Out of Business
4. Secondary Transaction - Private 01-Mar-2006 000.00 Completed Generating Revenue
3. Later Stage VC 20-May-2005 00.000 000.00 Completed Generating Revenue
2. Early Stage VC 22-Jul-2001 $23.9M $26.8M Completed Startup
1. Early Stage VC 01-Apr-2001 $2.88M $2.88M Completed Startup
To view De Novo Pharmaceuticals’s complete valuation and funding history, request access »

De Novo Pharmaceuticals Executive Team (4)

Name Title Board Seat Contact Info
Philip Dean Chief Executive Officer, Executive Director & Chief Scientific Officer
Steve Beasley Chief Business Officer
You’re viewing 2 of 4 executive team members. Get the full list »

De Novo Pharmaceuticals Board Members (3)

Name Representing Role Since
Amit Agarwal De Novo Pharmaceuticals Board Member 000 0000
Frederick Fahid De Novo Pharmaceuticals Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

De Novo Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial